北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 眼科  > 期刊论文
学科主题: 临床医学
题名:
Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion
作者: Tao, Y.1,2; Hou, J.1; Jiang, Y-R1; Li, X-X1; Jonas, J. B.2
关键词: bevacizumab ; central retinal vein occlusion ; triamcinolone acetonide
刊名: EYE
发表日期: 2010-05-01
DOI: 10.1038/eye.2009.220
卷: 24, 期:5, 页:810-815
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Ophthalmology
研究领域[WOS]: Ophthalmology
关键词[WOS]: RANDOMIZED CLINICAL-TRIAL ; INTRAOCULAR-PRESSURE ; INJECTION ; MANAGEMENT ; AVASTIN ; SECONDARY ; SAFETY
英文摘要:

Purpose To compare the effect of intravitreal bevacizumab vs intravitreal triamcinolone for the treatment of non-ischaemic central retinal vein occlusion (CRVO).

Methods The comparative nonrandomized retrospective clinical interventional study included 72 patients with non-ischaemic CRVO, divided into a bevacizumab group of 30 patients (1.25 mg bevacizumab) and a triamcinolone group of 42 patients (4.0 mg triamcinolone). All patients were consecutively included. At baseline, both study groups did not vary significantly in visual acuity, macular thickness, and duration of symptoms (191 +/- 300 days vs 222 +/- 256 days). The minimal follow-up was 3 months (mean: 7.8 +/- 4.3 months; range:3-12 months). During follow-up, 1.3 +/- 0.4 re-injections of the triamcinolone group (range: 1-2 injections) and 2.7 +/- 1.8 re-injections of bevacizumab (range:1-6 injections) were administered.

Results In both study groups, the mean visual acuity increased significantly (P<0.001) from baseline during follow-up. The differences in gain in visual acuity were not statistically significant (P>0.40) between both study groups at any time during follow-up. The mean macular thickness decreased significantly (P<0.001) in both study groups, with the reduction being significantly (P = 0.006) more pronounced in the triamcinolone group. Intraocular pressure increased significantly (P<0.001) in the triamcinolone group.

Conclusions In long-standing non-ischaemic CRVO, intravitreal bevacizumab and intravitreal triamcinolone are both associated with a comparable gain in visual acuity. The reduction in macular oedema was more marked in the triamcinolone group. In view of the potential complications of intravitreal triamcinolone in terms of intraocular pressure rise and cataractogenesis, bevacizumab may be preferred compared with triamcinolone for intravitreal use in non-ischaemic CRVO. Eye (2010) 24, 810-815; doi:10.1038/eye.2009.220; published online 21 August 2009

语种: 英语
所属项目编号: 7062065
项目资助者: Beijing Natural Science Foundation, Beijing, China
WOS记录号: WOS:000277592900010
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/54602
Appears in Collections:北京大学第二临床医学院_眼科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100044, Peoples R China
2.Univ Heidelberg, Med Fac Mannheim, Dept Ophthalmol, Heidelberg, Germany

Recommended Citation:
Tao, Y.,Hou, J.,Jiang, Y-R,et al. Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion[J]. EYE,2010,24(5):810-815.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Tao, Y.]'s Articles
[Hou, J.]'s Articles
[Jiang, Y-R]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Tao, Y.]‘s Articles
[Hou, J.]‘s Articles
[Jiang, Y-R]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace